Swiss Medica Inc., Innovative Products That Improve Peoples' Lives

10/12/2004 11:23:19 AM ET

SWISS MEDICA’S RECENT GNC STORE ORDER SETS NEW MILESTONE: 024 PAIN RELIEF PRODUCT

DISTRIBUTION IN OVER 1,100 RETAIL STORES THROUGHOUT CANADA

Stock Symbol: OTC BB: SWME

October 12, 2004

SWISS MEDICA’S RECENT GNC STORE ORDER SETS NEW MILESTONE: 024 PAIN RELIEF PRODUCT

DISTRIBUTION IN OVER 1,100 RETAIL STORES THROUGHOUT CANADA

Toronto, Canada – Swiss Medica’s recent order of the 024™ Essential Oil Pain Neutralizer product for all 140

GNC stores in Canada pushed the total number of retail store outlets, which offer the 024 pain relief product,

past the 1,100 mark. “We are delighted to announce this milestone,” said Grant Johnson. “All of our preparatory

efforts, during the past nine months, appear to be reaching fruition in the current quarter.”

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our

market share through focused distribution strategies in multiple sales channels. Swiss Medica’s mission is to be

a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please

visit our websites at www.swissmedica.com and

Swiss Medica’s flagship product, the 024™ Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The

024™ pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits

by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout

Canada in leading pharmacies and natural food stores. It is available in the United States and elsewhere by

visiting

, for ordering details and store locators.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the

United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking

statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close

transactions being contemplated, risks related to international sales and potential foreign currency exchange

fluctuations, continued acceptance of Swiss Medica’s products, increased levels of competition, technological

changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s

periodic reports filed with the United States Securities and Exchange Commission and other regulatory

authorities.

Investor Relations Contact:

David Jones

Swiss Medica

1-866-485-4243